All In Biotech

Drug Trial Radar · NCT00247273

A Study of Monthly Risedronate for Osteoporosis

A Phase III, Multicenter, Double-blind, Randomized, Active-controlled, Parallel Group, Non-inferiority Study Comparing 150 mg Risedronate Monthly With 5 mg Risedronate Daily in the Treatment of Postmenopausal Osteoporosis (PMO)

Last checked: Nov 20, 2026Latest source record: Apr 22, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,294 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,294

Actual

Start

Oct 2005

Primary completion

Mar 2008

Study completion Apr 2008

Sponsor

Lead sponsor
Warner ChilcottIndustry
Sponsor type
Industry
Collaborators
Sanofi
First posted
Nov 1, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
Female only, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this trial is to study the efficacy of a single-dose monthly dosing regimen as compared to the standard daily dosing regimen of risedronate 5 mg daily.

Conditions

  • Postmenopausal Osteoporosis

Interventions

  • risedronateDrug

    tablet, 5 mg risedronate, once a day for 2 years

  • risedronateDrug

    oral, 150 mg risedronate, once a month for 2 years

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at Month 12-Endpoint in Women With Postmenopausal Osteoporosis, Primary Efficacy PopulationTime frame: Baseline to Month 12 - Endpoint

Locations

49 sites in 14 countries. Site status is shown where the registry gives one.

  • Research Site

    Lakewood, Colorado

  • Research Site

    Gainesville, Georgia

  • Research Site

    Bethesda, Maryland

  • Research Site

    Omaha, Nebraska

  • Research Site

    West Haverstraw, New York

  • Research Site

    Cincinnati, Ohio

  • Research Site

    Portland, Oregon

  • Research Site

    Capital Federal, Argentina

  • Research Site

    Buenos Aires, Buenos Aires, Argentina

  • Research Site

    Geelong, Australia

  • Research Site

    Heidelberg, Victoria, Australia

  • Research Site

    Saint Leonards, Australia

  • Research Site

    Brussels, Belgium

  • Research Site

    Ghent, Belgium

  • Research Site

    Leuven, Belgium

  • Research Site

    Liège, Belgium

  • Research Site

    Mont Godinne, Belgium

  • Research Site

    Rio de Janeiro, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    Calgary, Canada

  • Research Site

    Montreal, Canada

  • Research Site

    Sainte-Foy, Canada

  • Research Site

    Saskatoon, Canada

  • Research Site

    Pärnu, Estonia

  • Research Site

    Tartu, Estonia

  • Research Site

    Helsinki, Finland

  • Research Site

    Kuopio, Finland

  • Research Site

    Oulu, Finland

  • Research Site

    Turku, Finland

  • Research Site

    Amiens, France

  • Research Site

    Lyon, France

  • Research Site

    Orléans, France

  • Research Site

    Paris, France

  • Research Site

    Toulouse, France

  • Research Site

    Vandœuvre-lès-Nancy, France

  • Research Site

    Balatonfüred, Hungary

  • Research Site

    Budapest, Hungary

  • Research Site

    Győr, Hungary

  • Research Site

    Miskolc, Hungary

  • Research Site

    Nagykanizs, Hungary

Showing 40 of 49 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.